[go: up one dir, main page]

GB202020502D0 - Antibody composistion for treatment of corona virus infection - Google Patents

Antibody composistion for treatment of corona virus infection

Info

Publication number
GB202020502D0
GB202020502D0 GBGB2020502.7A GB202020502A GB202020502D0 GB 202020502 D0 GB202020502 D0 GB 202020502D0 GB 202020502 A GB202020502 A GB 202020502A GB 202020502 D0 GB202020502 D0 GB 202020502D0
Authority
GB
United Kingdom
Prior art keywords
composistion
antibody
treatment
virus infection
corona virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2020502.7A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vlaams Instituut voor Biotechnologie VIB
Original Assignee
Vlaams Instituut voor Biotechnologie VIB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vlaams Instituut voor Biotechnologie VIB filed Critical Vlaams Instituut voor Biotechnologie VIB
Priority to GBGB2020502.7A priority Critical patent/GB202020502D0/en
Publication of GB202020502D0 publication Critical patent/GB202020502D0/en
Priority to CA3198333A priority patent/CA3198333A1/en
Priority to PCT/EP2021/087602 priority patent/WO2022136685A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C07K16/104—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
GBGB2020502.7A 2020-12-23 2020-12-23 Antibody composistion for treatment of corona virus infection Ceased GB202020502D0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
GBGB2020502.7A GB202020502D0 (en) 2020-12-23 2020-12-23 Antibody composistion for treatment of corona virus infection
CA3198333A CA3198333A1 (en) 2020-12-23 2021-12-23 Antibody compositions for treatment of corona virus infection
PCT/EP2021/087602 WO2022136685A1 (en) 2020-12-23 2021-12-23 Antibody compositions for treatment of corona virus infection

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2020502.7A GB202020502D0 (en) 2020-12-23 2020-12-23 Antibody composistion for treatment of corona virus infection

Publications (1)

Publication Number Publication Date
GB202020502D0 true GB202020502D0 (en) 2021-02-03

Family

ID=74221492

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2020502.7A Ceased GB202020502D0 (en) 2020-12-23 2020-12-23 Antibody composistion for treatment of corona virus infection

Country Status (3)

Country Link
CA (1) CA3198333A1 (en)
GB (1) GB202020502D0 (en)
WO (1) WO2022136685A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114891097A (en) * 2021-09-16 2022-08-12 中国科学院微生物研究所 Alpaca source nano antibody and application thereof

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202210573D0 (en) * 2022-07-19 2022-08-31 Autolus Ltd Antibodies against SARS-CoV-2 and uses thereof

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE420178T1 (en) 1992-08-21 2009-01-15 Univ Bruxelles IMMUNOGLOBULINS WITHOUT LIGHT CHAIN
US6838254B1 (en) 1993-04-29 2005-01-04 Conopco, Inc. Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae
FR2708622B1 (en) 1993-08-02 1997-04-18 Raymond Hamers Recombinant vector containing a sequence of a structural lipoprotein gene for the expression of nucleotide sequences.
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
CA2258518C (en) 1996-06-27 2011-11-22 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Recognition molecules interacting specifically with the active site or cleft of a target molecule
AU3596599A (en) 1998-01-26 1999-08-09 Unilever Plc Method for producing antibody fragments
EP1141711A1 (en) 1999-01-05 2001-10-10 Unilever Plc Binding of antibody fragments to solid supports
WO2000043507A1 (en) 1999-01-19 2000-07-27 Unilever Plc Method for producing antibody fragments
BR0009866A (en) 1999-04-22 2002-01-08 Unilever Nv Viral infection inhibition method, use of a monovalent antigen binding protein, food product, pharmaceutical or cosmetic composition, monovalent antigen binding protein, nucleotide sequence, expression vector, host cell, and selection and selection methods. identification of an antigen binding protein
US6479280B1 (en) 1999-09-24 2002-11-12 Vlaams Interuniversitair Institutuut Voor Biotechnologie Vzw Recombinant phages capable of entering host cells via specific interaction with an artificial receptor
WO2001040310A2 (en) 1999-11-29 2001-06-07 Unilever Plc Immobilisation of proteins using a polypeptide segment
DK1233987T3 (en) 1999-11-29 2009-09-28 Bac Ip B V Immobilized single-domain antigen-binding molecules
ATE428733T1 (en) 2000-03-14 2009-05-15 Unilever Nv VARIABLE DOMAIN OF THE HEAVY CHAIN OF AN ANTIBODY TO HUMAN NUTRITIONAL LIPASES AND THEIR USES
US20030190598A1 (en) 2000-05-26 2003-10-09 Jasmid Tanha Single-domain antigen-binding antibody fragments derived from llama antibodies
US20040053340A1 (en) 2000-12-13 2004-03-18 De Haard Johannes Joseph Protein arrays
US7371849B2 (en) 2001-09-13 2008-05-13 Institute For Antibodies Co., Ltd. Methods of constructing camel antibody libraries
JP2005289809A (en) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) Mutant heavy chain antibody
WO2003050531A2 (en) 2001-12-11 2003-06-19 Algonomics N.V. Method for displaying loops from immunoglobulin domains in different contexts
AU2002360068B2 (en) 2001-12-21 2009-09-03 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Method for cloning of variable domain sequences
EP1461085A2 (en) 2002-01-03 2004-09-29 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Immunoconjugates useful for treatment of tumours
AU2003286004A1 (en) 2002-11-08 2004-06-07 Ablynx N.V. Single domain antibodies directed against interferon- gamma and uses therefor
JP2006520584A (en) 2002-11-08 2006-09-14 アブリンクス エン．ヴェー． Stabilized single domain antibody
WO2004062551A2 (en) 2003-01-10 2004-07-29 Ablynx N.V. RECOMBINANT VHH SINGLE DOMAIN ANTIBODY FROM CAMELIDAE AGAINST VON WILLEBRAND FACTOR (vWF) OR AGAINST COLLAGEN
DE60334645D1 (en) 2003-11-07 2010-12-02 Ablynx Nv CAMELIDAE HEAVY CHAIN ANTIBODIES VHHS AGAINST EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AND ITS USE
BRPI0518151A2 (en) 2004-10-13 2009-06-16 Ablynx Nv polypeptides against amyloid-beta, nucleic acid encoding such polypeptide, composition comprising such polypeptide, method for producing a polypeptide and use thereof
JP2008528010A (en) 2005-01-31 2008-07-31 アブリンクス ナームローゼ フェンノートシャップ Methods for creating variable domain sequences of heavy chain antibodies
EP3613767A1 (en) 2005-05-18 2020-02-26 Ablynx N.V. Improved nanobodiestm against tumor cecrosis factor-alpha
KR101414438B1 (en) 2005-05-20 2014-07-10 아블린쓰 엔.브이. Single domain vhh antibodies against von willebrand factor
JP2010500876A (en) 2006-08-18 2010-01-14 アブリンクス エン．ヴェー． Amino acid sequence directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6 mediated signaling
CA2678218A1 (en) 2007-02-21 2008-08-28 Ablynx N.V. Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization
CN101796072B (en) 2007-05-24 2014-09-24 埃博灵克斯股份有限公司 Amino acid sequences against RANK-L and polypeptides comprising same for the treatment of bone diseases and disorders
SG10201605048XA (en) 2011-06-23 2016-07-28 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
AU2015261536B2 (en) 2014-05-16 2020-05-07 Ablynx Nv Improved immunoglobulin variable domains
WO2021156490A2 (en) 2020-02-06 2021-08-12 Vib Vzw Corona virus binders
CN112094343B (en) * 2020-09-25 2022-05-13 中国科学技术大学 Alpaca source nano antibody combined with SARS-CoV-2 RBD

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114891097A (en) * 2021-09-16 2022-08-12 中国科学院微生物研究所 Alpaca source nano antibody and application thereof
CN114891097B (en) * 2021-09-16 2023-01-24 中国科学院微生物研究所 An alpaca-derived nanobody and its application

Also Published As

Publication number Publication date
WO2022136685A1 (en) 2022-06-30
CA3198333A1 (en) 2022-06-30

Similar Documents

Publication Publication Date Title
LT4204421T (en) Compounds and methods for treatment of viral infections
IL315102A (en) Compounds and methods for treatment of viral infections
PL4157272T3 (en) Remdesivir for the treatment of viral infections
SG11202109683TA (en) Antibodies and methods for treatment of influenza a infection
EP3773632A4 (en) METHODS OF TREATMENT OF EGFRVIII-EXPRESSING GLIOBLASTOMAS
GB202020502D0 (en) Antibody composistion for treatment of corona virus infection
IL308478A (en) Methods and compositions for treatment of viral infection
GB2595513B (en) Treatment of infections
IL281447A (en) Methods and compounds for the treatment of viral infections
EP4404939A4 (en) HYGROMYCIN A FOR THE TREATMENT OF DISEASES AND INFECTIONS
EP4121092C0 (en) HYBRID INTERFERONS FOR THE TREATMENT OF VIRAL INFECTIONS
ZA202212662B (en) Use of compounds for treating viral infections
EP4351546A4 (en) HOST-DIRECTED DRUG COMBINATIONS FOR THE TREATMENT OF VIRUS INFECTIONS
EP4190800A4 (en) Peptide for treatment of corona virus infection disease covid-19 and use thereof
EP4153302C0 (en) TREATMENT OF VIRAL RESPIRATORY INFECTIONS
EP4025212B8 (en) Isoxazole-3-carboxamide derivatives and their use for treatment of diseases caused by virus infection
EP4203965A4 (en) Compounds and methods for prevention and treatment of virus infections
EP4146227A4 (en) TREATMENT OF VIRUS INFECTIONS
GB202117798D0 (en) Antibodies for the prevention and treatment of corona virus caused diseases
HK40088047A (en) Inhibitors of c5a for the treatment of corona virus infection
AU2020901054A0 (en) Methods for treatment of virus infections
EP4322967A4 (en) Treatment of virus infections
EP3911413C0 (en) SUBSTITUTED CHROME-4-ONE FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTIONS
IL280340B (en) Antibodies, peptides and their combinations for the treatment and prevention of corona virus infections
GB202312669D0 (en) Treatment of viral infections

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)